Invenio Imaging Announces Clinical Research Collaboration Agreement

Summation

  • , a leader in intraoperative fresh tissue imaging and artificial intelligence, today announced that it has entered into a research collaboration agreement with the Lung Cancer Initiative at Johnson &.
  • “In this important clinical study, we will develop a novel image analysis algorithm based on machine learning to provide physicians with real-time feedback determining whether a biopsy sample contains cancer”, says Chris Freudiger, PhD, Co-Founder and CTO of Invenio Imaging.
  • The NIO® Laser Imaging Systems allows rapid imaging of fresh tissue biopsies with subcellular resolution in the procedure room with minimal preparation while preserving the sample for additional downstream pathology analysis.

Invenio Imaging, Inc., a leader in intraoperative fresh tissue imaging and artificial intelligence, today announced that it has entered into a research collaboration agreement with the Lung Cancer Initiative at Johnson & Johnson* to develop and validate the NIO® Lung Cancer Reveal image analysis algorithm to assist physicians in the evaluation of bronchoscopic lung biopsies.

The NIO® Laser Imaging Systems allows rapid imaging of fresh tissue biopsies with subcellular resolution in the procedure room with minimal preparation while preserving the sample for additional downstream pathology analysis. “In this important clinical study, we will develop a novel image analysis algorithm based on machine learning to provide physicians with real-time feedback determining whether a biopsy sample contains cancer”, says Chris Freudiger, PhD, Co-Founder and CTO of Invenio Imaging.

“We are excited to undertake this ambitious clinical study in collaboration with the Lung Cancer Initiative”, says Jay Trautman, PhD, Co-Founder and CEO of Invenio Imaging.

NIO® Lung Cancer Reveal has not been cleared by the Food and Drug Administration for clinical use in the United States.

More News

Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06)

Investigator-Initiated Phase 2 study is being conducted at Northwestern University in cooperation with Moleculin. Trial combines WP1066 and radiation, which demonstrated both significant therapeutic response and immune "memory" in glioblastoma animal models

AbbVie and Gilgamesh Pharmaceuticals | Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders

Under terms of the agreement, AbbVie and Gilgamesh Pharmaceuticals have agreed to research and develop a portfolio of next-generation therapeutics for psychiatric disorders.

PharmaLogic Announces Opening of Radiopharmaceutical Production Facility in New York City

Acquired in 2022, the facility has undergone extensive renovations and boasts state-of-the-art equipment, signifying the companys significant investment in fostering the development of novel radiopharmaceuticals in the region.

By using this website you agree to accept Medical Device News Magazine Privacy Policy